← All indications
Histiocytoma, Malignant Fibrous
The most commonly diagnosed soft tissue sarcoma. It is a neoplasm with a fibrohistiocytic appearance found chiefly in later adult life, with peak incidence in the 7th decade.
Drugs by status
Organizations
Organization Involved with Phase 3 Indications (13)
- National Cancer Institute (NCI)
- Children's Cancer and Leukaemia Group
- Cooperative Weichteilsarkom Study Group
- European Paediatric Soft Tissue Sarcoma Study Group
- University of Manchester
- University of Milan
- University of Padova
- University of Bristol
- Dutch Childhood Oncology Group
- Societe Internationale d'Oncologie Pediatrique (SIOP)
- University of Ulm
- Erasmus University Rotterdam
- Italian Association for Pediatric Hematology Oncology
Organization Involved with Phase 2 Indications (24)
- Bristol-Myers Squibb
- Merck
- Genentech
- Pfizer
- Oncolytics Biotech
- Tracon Pharmaceuticals Inc.
- Cornell University
- Harvard University
- Jilin University
- Northwestern University
- Oregon Health and Science University
- University of South Florida
- University of Toronto
- Wake Forest University
- Mayo Clinic
- University of California, Los Angeles
- Royal Marsden Hospital NHS Trust
- University of Texas at Houston
- Maria Sklodowska Curie Children's Hospital
- Washington University in St. Louis
- National Comprehensive Cancer Network
- Memorial Sloan-Kettering Cancer Center
- Iovance
- St. Jude Children's Hospital
Organization Involved with Phase 1 Indications (8)
Organization Involved with Other Experimental Indications (1)